Scientific educational review. Updated 10 November 2026. Clinical treatment must follow patient-specific assessment and locally approved prescribing information.
Overview
Sympathomimetics enhance sympathetic effector responses by directly stimulating adrenergic receptors, indirectly increasing endogenous norepinephrine, or combining both mechanisms. They are indispensable in anaphylaxis, shock, acute bronchospasm and selected hypotensive or cardiac conditions, but their receptor selectivity strongly determines benefit and risk [1–3].
Receptor signaling and drug examples
- α1 (Gq): phenylephrine raises vascular resistance through smooth-muscle calcium signaling.
- α2 (Gi/o): clonidine and dexmedetomidine mainly reduce central sympathetic outflow; despite being agonists they are not generally pressor drugs.
- β1 (Gs): dobutamine increases inotropy, with additional receptor effects depending on dose and vascular state.
- β2 (Gs): salbutamol/albuterol and terbutaline relax bronchial smooth muscle.
- β3 (Gs): mirabegron relaxes detrusor muscle and is used for overactive bladder.
- Mixed α/β: epinephrine stimulates α1, β1 and β2; norepinephrine has potent α1 with β1 effects.
- Indirect or mixed agents: amphetamine facilitates catecholamine release; ephedrine has both direct and indirect actions [1].
Anaphylaxis and epinephrine
For suspected anaphylaxis, intramuscular epinephrine into the mid-outer thigh is first-line treatment. It counteracts vasodilation and edema through α1, supports cardiac output via β1 and relieves bronchospasm via β2. Repeat dosing and urgent medical support may be necessary. Antihistamines and corticosteroids do not replace epinephrine; routine delay to administer these adjuncts risks harm. IV epinephrine should be reserved for monitored specialist settings because of severe arrhythmia and ischemia risks [1,2].
Shock and other clinical uses
Norepinephrine is a preferred initial vasopressor in many septic-shock protocols, combined with fluids, source control and reassessment rather than fixed empiric dosing. Dobutamine may be added in selected low-output states with persistent hypoperfusion. In asthma, inhaled short-acting β2 agonists relieve acute bronchospasm but asthma maintenance needs ICS-containing treatment. Oral decongestant sympathomimetics such as pseudoephedrine can cause hypertension and insomnia; use with caution in cardiovascular disease [1,3].
Pharmacokinetics and interactions
Catecholamines are rapidly metabolized by COMT and MAO pathways and usually require parenteral administration in emergencies. Oral phenylephrine lacks well-established efficacy as a decongestant at standard doses; do not equate it with injectable phenylephrine. Monoamine oxidase inhibitors, tricyclic antidepressants and some stimulant combinations can potentiate adrenergic effects. Beta blockers may modify hemodynamic response to epinephrine, but are not reasons to withhold emergency epinephrine in anaphylaxis [1,2].
Toxicity and clinical monitoring
Sympathomimetics can cause tachycardia, hypertension, tremor, hypokalemia, arrhythmias and myocardial ischemia, depending on receptor profile and dose. IV vasopressors require monitored infusion, vascular access considerations and evaluation for tissue ischemia/extravasation. Receptor-specific selection and titration are more meaningful than crude categorization as ‘stimulants’ [1,3].
References
- Brunton LL, Knollmann BC, editors. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw Hill; 2023.
- Shaker MS, Wallace DV, Golden DBK, et al. Anaphylaxis: a 2023 practice parameter update. Ann Allergy Asthma Immunol. 2023. Available from: https://www.aaaai.org/Aaaai/media/Media-Library-PDFs/Allergist%20Resources/Statements%20and%20Practice%20Parameters/Anaphylaxis-2023-grade-document.pdf
- Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181–1247. Available from: https://www.sccm.org/clinical-resources/guidelines/guidelines/surviving-sepsis-campaign-guidelines-2021
Medical & AI Disclaimer
The information provided on Sumathi Publications is for general educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare professional regarding any medical condition or treatment decision.
We strive to keep our content accurate and up to date; however, some content may be created or assisted using artificial intelligence (AI) and may contain errors or omissions. All information should be independently verified before use. Reliance on any content provided by Pharmacology Mentor is at your own risk.